Page 148 - 南京医科大学自然版

第46卷第9期
·1418 · 南 京 医 科 大 学 学 报 2026年9月

［2］ ZHANG P，YUE L，LENG Q Q，et al. Targeting FGFR for Precis Oncol，2024，8：e2400138
cancer therapy［J］. J Hematol Oncol，2024，17（1）：39 ［16］LI R，LINSCOTT J，CATTO J W F，et al. FGFR inhibition
［3］ KAM A E，MASOOD A，SHROFF R T. Current and emerg⁃ in urothelial carcinoma［J］. Eur Urol，2025，87（2）：110-
ing therapies for advanced biliary tract cancers［J］. Lan⁃ 122
cet Gastroenterol Hepatol，2021，6（11）：956-969 ［17］KIDO K，NOJIMA S，MOTOOKA D，et al. Ovarian high⁃
［4］ HO J，FIOCCO C，SPENCER K. Treating biliary tract can⁃ grade serous carcinoma cells with low SMARCA4 expres⁃
cers：new targets and therapies［J］. Drugs，2022，82（17）： sion and high SMARCA2 expression contribute to plati⁃
1629-1647 num resistance［J］. J Pathol，2023，260（1）：56-70
［5］ KATOH M，LORIOT Y，BRANDI G，et al. FGFR⁃targeted ［18］APFELBAUM A A，MORIN E，STURM D，et al. A di⁃
therapeutics：clinical activity，mechanisms of resistance verse landscape of FGFR alterations and co ⁃ mutations
and new directions［J］. Nat Rev Clin Oncol，2024，21（4）： suggests potential therapeutic strategies in pediatric low⁃
312⁃329 grade gliomas［J］. Nat Commun，2025，16：7018
［6］ POZNIAK M，POREBSKA N，JASTRZEBSKI K，et al. ［19］XIE M，LIN Z Y，JI X Y，et al. FGF19/FGFR4⁃mediated
Modular self ⁃ assembly system for development of oligo⁃ elevation of ETV4 facilitates hepatocellular carcinoma
meric，highly internalizing and potent cytotoxic conju⁃ metastasis by upregulating PD⁃L1 and CCL2［J］. J Hepa⁃
gates targeting fibroblast growth factor receptors［J］. J tol，2023，79（1）：109-125
Biomed Sci，2021，28（1）：69 ［20］YEMELYANENKO J，BHIN J，VAN DER BURG E，et al.
［7］ PANT S，PARK J O，SU W C，et al. Erdafitinib in patients C⁃terminal truncation and fusion partner determine onco⁃
with FGFR⁃altered advanced or metastatic cholangiocar⁃ genicity of FGFR3［J］. Cancer Res，2026，86（6）：1372-
cinoma［J］. Clin Cancer Res，2026，32（6）：1136-1144 1391
［8］ YUE H，WANG Y，ZHANG N，et al. Small⁃molecule FG⁃ ［21］OGURA K，ELKRIEF A，BOWMAN A S，et al. Prospec⁃
FR ⁃ targeted medicinal chemistry：advances since 2020 tive clinical genomic profiling of ewing sarcoma：ERF and
and future perspectives［J］. Eur J Med Chem，2025，300： FGFR1 mutations as recurrent secondary alterations of po⁃
118117 tential biologic and therapeutic relevance［J］. JCO Precis
［9］ LIN Q M，CHEN X J，QU L Z，et al. Characterization of Oncol，2022，6：e2200048
the cholangiocarcinoma drug pemigatinib against FGFR ［22］LIU X H，MEI W X，YAO Y R，et al. Current insights and
gatekeeper mutants［J］. Commun Chem，2022，5（1）：100 barriers in FGFR⁃mediated signaling in lung cancer［J］.
［10］BONI J，FERNÁNDEZ⁃GONZÁLEZ M，HAN H，et al. Con⁃ Eur J Med Chem，2025，296：117897
currence of FGFR1 mutations modulates oncogenesis in ［23］CHEN Y H，DAI S Y，CHENG C S，et al. Lenvatinib and
glioneuronal tumors［J］. EMBO J，2025，44（24）：7513- immune⁃checkpoint inhibitors in hepatocellular carcino⁃
7540 ma：mechanistic insights，clinical efficacy，and future per⁃
［11］GIACOMINI A，TARANTO S，GAZZAROLI G，et al. spectives［J］. J Hematol Oncol，2024，17（1）：130
The FGF/FGFR/c ⁃ Myc axis as a promising therapeutic ［24］SHIGETA K，MATSUMOTO K，KITAOKA S，et al. Profiling
target in multiple myeloma［J］. J Exp Clin Cancer Res， fibroblast growth factor receptor 3 expression based on
2024，43（1）：294 the immune microenvironment in upper tract urothelial
［12］CAI B H，LIU Y，CHONG Y T，et al. A truncated deriva⁃ carcinoma［J］. Eur Urol Oncol，2024，7（6）：1338-1349
tive of FGFR1 kinase cooperates with FLT3 and KIT to ［25］KOMURA K，HIROSUNA K，TOKUSHIGE S，et al. The
transform hematopoietic stem cells in syndromic and de impact of FGFR3 alterations on the tumor microenviron⁃
novo AML［J］. Mol Cancer，2022，21（1）：156 ment and the efficacy of immune checkpoint inhibitors in
［13］LYU X，CAI R，HAN B，et al. FGFR1⁃amplified colorec⁃ bladder cancer［J］. Mol Cancer，2023，22（1）：185
tal cancer：a distinct prognostic subtype identified ［26］SONG Y X，PENG Y，QIN C P，et al. Fibroblast growth
through integrated genomic and immunohistochemical factor receptor 3 mutation attenuates response to immune
profiling［J］. ESMO Open，2025，10（9）：105561 checkpoint blockade in metastatic urothelial carcinoma
［14］STEIN L，MURUGESAN K，REESER J W，et al. FGFR2⁃ by driving immunosuppressive microenvironment［J］. J
fusions define a clinically actionable molecular subset of Immunother Cancer，2023，11（9）：e006643
pancreatic cancer［J］. NPJ Precis Oncol，2024，8（1）：207 ［27］OUYANG Y，OU Z W，ZHONG W L，et al. FGFR3 altera⁃
［15］JAYAKRISHNAN T，BACA Y，XIU J，et al. Molecular dif⁃ tions in bladder cancer stimulate serine synthesis to in⁃
ferences with therapeutic implications in early⁃onset com⁃ duce immune⁃inert macrophages that suppress T⁃cell re⁃
pared with average ⁃ onset biliary tract cancers［J］. JCO cruitment and activation［J］. Cancer Res，2023，83（24）：